Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.7, 2008-01, pp. : 587-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk factors for Rhabdomyolysis with Simvastatin and Atorvastatin

By Golomb Beatrice Evans Marcella

Drug Safety, Vol. 29, Iss. 12, 2006-01 ,pp. : 1191-1191

Adis International

Access to resources Recommend Favorite

Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin

By Ronaldson Kathlyn J.

Drug Safety, Vol. 29, Iss. 11, 2006-01 ,pp. : 1061-1067

Adis International

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors: Nasal polyps (first report with atorvastatin and simvastatin): 3 case reports

Reactions Weekly, Vol. 1, Iss. 1047, 2005-01 ,pp. : 10-11

Adis International

Access to resources Recommend Favorite

Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin

By Hochman Jerome H. Pudvah Nicole Qiu Julia Yamazaki Masayo Tang Cuyue Lin Jiunn H. Prueksaritanont Thomayant

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1686-1691

Springer Publishing Company

Access to resources Recommend Favorite

Atorvastatin/simvastatin: Muscular disorders: 4 case reports

Reactions Weekly, Vol. 1, Iss. 1080, 2005-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite